Novo Nordisk A/S (NVO)
Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NVO
- Rev/Share 68.2827
- Book/Share 31.2062
- PB 14.5232
- Debt/Equity 0.857
- CurrentRatio 0.7386
- ROIC 0.3875
- MktCap 2011672953933.6895
- FreeCF/Share 16.8361
- PFCF 26.9142
- PE 19.2328
- Debt/Assets 0.2427
- DivYield 0.0227
- ROE 0.8124
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | NVO | BMO Capital Markets | Outperform | Market Perform | -- | $64 | April 17, 2025 |
| Upgrade | NVO | Kepler | Hold | Buy | -- | -- | March 13, 2025 |
| Downgrade | NVO | Stifel | Buy | Hold | -- | -- | March 3, 2025 |
| Initiation | NVO | Morgan Stanley | -- | Equal Weight | -- | -- | Feb. 12, 2025 |
| Upgrade | NVO | Bernstein | Underperform | Market Perform | -- | -- | Jan. 6, 2025 |
News
Novo Nordisk: The Market Doesn't Get It
Published: July 11, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk remains dominant in diabetes and obesity care, with strong growth and expanding market share despite recent investor concerns. The company's pipeline, especially the oral GLP-1 and Alzheimer's trial, offers significant long-term upside. The company needs to grow its top-line at mid-% to justify its current valuation. By assuming the market growth rate, the company is massively undervalued.
Read More
Smart Money Going in Senior Health: Key Stocks in Elderly Care
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Neutral
RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.
Read More
Is Novo Nordisk Increasing Dosage to Defend Wegovy's Edge in Obesity?
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity market.
Read More
Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
Published: July 09, 2025 by: CNBC
Sentiment: Positive
Hims & Hers Health announced plans to expand to Canada in 2026. Hims will offer generic copies of semaglutide drugs in Canada as Novo Nordisk loses patent protection.
Read More
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
Published: July 08, 2025 by: CNBC
Sentiment: Negative
Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.
Read More
Novo Nordisk submits higher Wegovy dose to the European Medicines Agency for approval
Published: July 08, 2025 by: Reuters
Sentiment: Positive
Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European Medicines Agency for approval, with one in three trial participants achieving 25% or more weight loss.
Read More
Hims & Hers Navigates Novo Nordisk Breakup And Compounding Lawsuits
Published: July 07, 2025 by: Benzinga
Sentiment: Negative
Hims & Hers Health, Inc. HIMS is currently experiencing a decline in its stock price, trading lower on Monday. The company's stock has plummeted approximately 18% over the past month, reflecting recent challenges.
Read More
Why Novo Nordisk (NVO) is a Top Value Stock for the Long-Term
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Are You Looking for a High-Growth Dividend Stock?
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novo Nordisk (NVO) have what it takes?
Read More
Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?
Published: July 04, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
Novo Nordisk: The Pullback Is Noise - The Buy Case Is Stronger Than Ever
Published: July 01, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk's fundamentals remain robust despite recent share price weakness, with strong sales and profit growth as well as a well-established pipeline. Concerns over CEO transition and compounding threats are overblown; FDA enforcement and strategic partnerships will redirect demand to branded Wegovy. An oral semaglutide approval later this year can help reignite share price momentum.
Read More
Mizuho's Jared Holz: Novo Nordisk is trying to come up with strategies to regain market share
Published: July 01, 2025 by: CNBC Television
Sentiment: Positive
Jared Holz, Mizuho Securities health care strategist, joins CNBC's 'Squawk on the Street' to discuss weight loss drug makers, how CVS is boosting access to Wegovy, and more.
Read More
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Published: June 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
6 International Stocks To buy in July
Published: June 27, 2025 by: 24/7 Wall Street
Sentiment: Positive
With over $5 trillion of new investment commitments to date, the U.S.
Read More
NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and strategic momentum.
Read More
Novo Nordisk to Expand Access to Wegovy with WeightWatchers Partnership
Published: June 26, 2025 by: WSJ
Sentiment: Positive
The pharmaceutical giant said WeightWatchers will work with CenterWell Pharmacy to fulfill and deliver Wegovy prescriptions.
Read More
Novo Nordisk ties up with WeightWatchers to sell Wegovy
Published: June 26, 2025 by: Reuters
Sentiment: Positive
Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug, Wegovy, starting July 1.
Read More
Novo Nordisk continues efforts to support patient access to authentic, FDA approved Wegovy® and prioritize patient safety
Published: June 26, 2025 by: PRNewsWire
Sentiment: Neutral
Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy® through NovoCare® Pharmacy Ro and LifeMD collaborations continue based on their commitment to providing safe and effective medical treatment for patients living with chronic diseases; dialogue with other companies ongoing A new $299 savings offer, available from July 1 – July 31, 2025, is designed to help new self-paying patients previously prescribed unapproved "semaglutide" start on FDA-approved Wegovy® PLAINSBORO, N.J. , June 26, 2025 /PRNewswire/ -- Novo Nordisk continues expansion of patient access to Wegovy® (semaglutide) injection 2.4 mg through a new collaboration with …
Read More
CHMP Backs NVO's Ozempic EU Label Update for Cardiovascular Indication
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients with PAD.
Read More
Can Novo Nordisk Regain Ground After Cutting Ties With Hims & Hers?
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
NVO ends its deal with HIMS over safety concerns tied to compounded Wegovy, hitting patient access and market share plans.
Read More
Hims & Hers: The Novo Nordisk Breakup Changes Nothing
Published: June 24, 2025 by: Seeking Alpha
Sentiment: Positive
The Novo Nordisk partnership ending does not alter my long-term bullish thesis on HIMS; the company is much more than just a GLP-1 play. HIMS' core value lies in its broad treatment offerings and disruptive model, not in partnerships with big pharma like NVO. Legal risks remain, but I believe HIMS is well-positioned to defend itself, and no legal action has been initiated by NVO yet.
Read More
EU drug regulator allows Novo Nordisk to include heart condition in Ozempic label
Published: June 23, 2025 by: Reuters
Sentiment: Positive
Novo Nordisk said on Monday the European drugs regulator has adopted a positive opinion for an update of the Ozempic label to include peripheral artery disease.
Read More
Novo Nordisk A/S: Ozempic® receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and comorbidities
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bagsværd, Denmark, 23 June 2025 – Novo Nordisk today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of the Ozempic® (once-weekly semaglutide) label to reflect the positive data from the STRIDE peripheral artery disease (PAD) functional outcomes trial.
Read More
Novo Nordisk Ends Partnership with Hims & Hers
Published: June 23, 2025 by: WSJ
Sentiment: Negative
The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations about Hims' compounding and deceptive marketing practices.
Read More
NVO Reports New Positive Phase III Data on Mim8 in Hemophilia A
Published: June 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk's Mim8 shows strong safety and patient preference in the phase IIIb hemophilia A study switching from Hemlibra to Mim8.
Read More
Hims & Hers shares drop after Novo Nordisk ends Wegovy collaboration over compounding practices
Published: June 23, 2025 by: Proactive Investors
Sentiment: Negative
Shares of Hims & Hers Health (NYSE:HIMS) fell around 30% on Monday after Novo Nordisk (NYSE:NVO) terminated its collaboration with the telehealth company, citing violations related to compounding and marketing of the weight-loss drug Wegovy. Novo said it ended Hims & Hers' access to the FDA-approved treatment through its NovoCare platform, alleging that the company engaged in illegal mass compounding and deceptive marketing.
Read More
Novo Nordisk under pressure, ends deal with Hims & Hers
Published: June 23, 2025 by: CNBC Television
Sentiment: Negative
CNBC's Angelica Peebles joins 'Squawk on the Street' with the latest details on the pharmaceutical space.
Read More
Novo Nordisk, Hims and Hers Shares Tumble on Severed Ties
Published: June 23, 2025 by: Schaeffers Research
Sentiment: Negative
Novo Nordisk A/S (NYSE:NVO) stock is down 5.3% to trade at $69.90 at last check, after the drugmaker's obesity drug CagriSema showed no clear advantage over Eli Lilly's (LLY) Zepbound.
Read More
Hims & Hers Stock Plunges as Novo Nordisk Abruptly Ends Partnership
Published: June 23, 2025 by: Barrons
Sentiment: Negative
Novo Nordisk accuses the telehealth company of breaking a law related to drug compounding.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Lars Fruergaard Jorgensen
- Employees 77406